WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
L1 and mug adj a	0

Database:
US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L3

Refine Search

Recall Text | Clear

Search History

DATE: Wednesday, March 12, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=AND			
L3	L1 and mug adj a	0	L3
L2	L1 and muga	0	L2
L1	anguillarum	79	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
L1 and vibrio	71

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L4

Refine Search

Recall Text | Clear

Search History

DATE: Wednesday, March 12, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=AND			
L4	L1 and vibrio	71	L4
L3	L1 and mug adj a	0	L3
L2	L1 and muga	0	L2
L1	anguillarum	79	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 71 returned.

☐ 1. Document ID: US 6525080 B1

L4: Entry 1 of 71 File: USPT Feb 25, 2003

US-PAT-NO: 6525080
DOCUMENT-IDENTIFIER: US 6525080 B1

TITLE: Thiazoline acid derivatives

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bergeron; Raymond J.	Gainesville	FL		

US-CL-CURRENT: 514/365

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 6521652 B1

L4: Entry 2 of 71 File: USPT Feb 18, 2003

US-PAT-NO: 6521652
DOCUMENT-IDENTIFIER: US 6521652 B1

TITLE: Thiazoline acid derivatives

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bergeron; Raymond J.	Gainesville	FL		

US-CL-CURRENT: 514/365

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 6518013 B1

L4: Entry 3 of 71 File: USPT Feb 11, 2003

US-PAT-NO: 6518013

DOCUMENT-IDENTIFIER: US 6518013 B1

TITLE: Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn O'Lin	Cary	NC		
Lambert; Dennis Michael	Cary	NC		
Petteway; Stephen Robert	Cary	NC		

US-CL-CURRENT: 435/5; 424/230.1, 530/300, 530/324, 530/325, 530/326

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 4. Document ID: US 6479055 B1

L4: Entry 4 of 71 File: USPT Nov 12, 2002

US-PAT-NO: 6479055
DOCUMENT-IDENTIFIER: US 6479055 B1

TITLE: Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bolognesi; Dani Paul	Durham	NC		
Matthews; Thomas James	Durham	NC		
Wild; Carl T.	Durham	NC		
Barney; Shawn O'Lin	Cary	NC		
Lambert; Dennis Michael	Cary	NC		
Petteway; Stephen Robert	Cary	NC		
Langlois; Alphonse J.	Durham	NC		

US-CL-CURRENT: 424/211.1; 424/186.1, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 5. Document ID: US 6462027 B2

L4: Entry 5 of 71 File: USPT Oct 8, 2002

US-PAT-NO: 6462027
DOCUMENT-IDENTIFIER: US 6462027 B2

TITLE: Delivery of nucleic acid into aquatic animals

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Poet; Steven E.	Winterville	GA		
Burnley; Victoria Vaughn	Athens	GA		

US-CL-CURRENT: 514/44; 424/184.1, 435/320.1, 435/325, 435/455, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 6454951 B1

L4: Entry 6 of 71 File: USPT Sep 24, 2002

US-PAT-NO: 6454951
DOCUMENT-IDENTIFIER: US 6454951 B1

TITLE: Photosensitive composition

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jori; Guilio	Padua			IT

US-CL-CURRENT: 210/748; 210/501, 210/755, 210/763, 210/764, 422/22, 428/403, 430/339, 502/163, 502/167, 502/522, 514/454 , 514/584, 514/587

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 6444448 B1

L4: Entry 7 of 71 File: USPT Sep 3, 2002

US-PAT-NO: 6444448
DOCUMENT-IDENTIFIER: US 6444448 B1

TITLE: Production of .beta.-glucan-mannan preparations by autolysis of cells under certain pH, temperature and time conditions

DATE-ISSUED: September 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wheatcroft; Ragini	Melbourne			AU
Kulandai; Joseph	Melbourne			AU
Gilbert; Robert White	Melbourne			AU
Sime; Keith James	Melbourne			AU
Smith; Craig Gordon	Melbourne			AU
Langeris; Willem Hendrik	Melbourne			AU

US-CL-CURRENT: 435/101; 424/234.1, 424/274.1, 424/278.1, 424/282.1, 424/93.5, 424/93.51, 426/60, 426/62, 426/656, 435/169, 435/170, 435/171, 435/259, 435/72, 435/95, 435/99, 514/54, 514/777

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 8. Document ID: US 6346514 B1

L4: Entry 8 of 71 File: USPT Feb 12, 2002

US-PAT-NO: 6346514
DOCUMENT-IDENTIFIER: US 6346514 B1

TITLE: Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof

DATE-ISSUED: February 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Green; Lawrence R.	Tacoma	WA		
Sinackevich; Nicolay V.	St. Petersburg			RU
Ivanov; Vadim T.	Moscow			RU
Mikhalyova; Inessa I.	Moscow			RU
Vaskovsky; Boris V.	Moscow			RU
Mikhaltsov; Alexander N.	St. Petersburg			RU
Khavinson; Vladimir K.	St. Petersburg			RU
Morozov; Vyacheslav G.	St. Petersburg			RU

US-CL-CURRENT: 514/17; 514/15, 514/16, 514/18

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 9. Document ID: US 6346252 B1

L4: Entry 9 of 71 File: USPT Feb 12, 2002

US-PAT-NO: 6346252
DOCUMENT-IDENTIFIER: US 6346252 B1

TITLE: Method of obtaining an antibacterial and/or antifungal extract from the algae, bonnemaisoniacea

DATE-ISSUED: February 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moigne; Jean-Yves	Kerinec			FR

US-CL-CURRENT: 424/195.17; 424/401, 424/78.02, 424/78.03, 424/78.07, 514/881, 514/944

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 10. Document ID: US 6327996 B1

L4: Entry 10 of 71 File: USPT Dec 11, 2001

US-PAT-NO: 6327996
DOCUMENT-IDENTIFIER: US 6327996 B1

TITLE: Biosecure zero-exchange system for maturation and growout of marine animals

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pruder; Gary David	Honolulu	HI		
Moss; Shaun McAlpine	Kaneohe	HI		
Tacon; Albert George Joseph	Kaneohe	HI		

US-CL-CURRENT: 119/207; 119/228, 119/234

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

Generate Collection | Print

Terms	Documents
L1 and vibrio	71

Display Format: CIT | Change Format

Previous Page Next Page

```
Set     Items   Description
S1       6849   V.ANGUILLARUM OR VIBRIO (1W) ANGUILLARUM
S2          3   S1 AND MUGA
S3          1   RD (unique items)
S4     395459   S1 AND VACCINE OR VACCINES
S5        723   S4 AND S1
S6        424   RD (unique items)
S7         48   S6 AND ATTENUATED
S8          0   S7 AND MUG
? t s7/3,ab/1-25
>>>No matching display code(s) found in file(s): 65, 129, 342, 345, 390,
   398, 765

 7/3,AB/1      (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

09716933   BIOSIS NO.: 199598171851
Vaccination in European salmonid aquaculture: A review of practices and
  prospects.
AUTHOR: Press C M(a); Lillehaug A
AUTHOR ADDRESS: (a)Dep. Morphology, Genetics Aquatic Biol., Norwegian Coll.
  Vet. Med., Box 8146 Dep. 0033 Oslo**Norway
JOURNAL: British Veterinary Journal  151 (1):p45-69 1995
ISSN: 0007-1935
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Disease control by vaccination is widely used in European
  salmonid aquaculture against vibriosis (%Vibrio% %anguillarum%),
  cold-water vibriosis (Vibrio salmonicida), yersiniosis or enteric
  redmouth disease (Yersinia ruckeri) and furunculosis (Aeromonas
  salmonicida subsp. salmonicida). The %vaccines% against the Vibrio spp.
  and Y. ruckeri have proven effective especially when administered by
  injection. Furunculosis %vaccines% have been less successful and have
  relied on combination with potent adjuvants to achieve acceptable
  protection. Application of modern molecular techniques to furunculosis
  research has delivered a crop of experimental %vaccines% that incorporate
  purified virulence factors and have shown increased protection during
  challenge. Gene technology has also been used to create a defined,
  non-reverting mutation in a strain of A. salmonicida, which has enhanced
  the feasibility of %attenuated% live %vaccines%. The development of
  experimental subunit %vaccines% against the viral infections and the
  continued advances in the field of immunostimulants, adjuvants and
  antigen carriers provide considerable promise for the future development
  of commercial %vaccines% for use in salmonid aquaculture.

1995


 7/3,AB/2      (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07705149   BIOSIS NO.: 000092040930
USE OF A RESTRICTION-DEFECTIVE VARIANT FOR THE CONSTRUCTION OF STABLE
  %ATTENUATED% STRAINS OF THE MARINE FISH PATHOGEN %VIBRIO%-%ANGUILLARUM%
AUTHOR: SINGER J T; CHOE W; SCHMIDT K A
AUTHOR ADDRESS: DEP. BIOCHEM., MICROBIOL. AND MOL. BIOL., UNIV. MAINE,
  ORONO, ME 04469.
JOURNAL: J MICROBIOL METHODS 13 (1). 1991. 49-60. 1991
FULL JOURNAL NAME: Journal of Microbiological Methods
CODEN: JMIMD
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: A method for the in vitro construction of stable %attenuated%
```

strains of the marine fish pathogen %Vibrio% %anguillarum% 775 is described. A cloned gene for a membrane-associated polypeptide, p40, that is required for virulence of V. anguillarum, was inactivated by insertion of a 1.5-kb kan fragment. The mutagenized p40-kan DNA sequence was introduced into a restriction-defective recipient strain of virulent V. anguillarum 775 by conjugal mobilization of a pBR322-p40-kan derivative from an Escherichia coli HB101 donor. A homologous recombinant of V. anguillarum 775 was selected that lost pBR322 sequences but that retained p40-kan DNA sequences. This strain was > 105-fold %attenuated% in virulence for rainbow trout, expressed a surface-exposed outer membrane protein, pOM2, that is also known to be required for virulence, and persisted in immunized fish for at least 9 days post-injection.

1991

7/3,AB/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

07544901 BIOSIS NO.: 000091096979
POLYPEPTIDES P40 POM2 AND PANGR ARE REQUIRED FOR IRON UPTAKE AND FOR VIRULENCE OF THE MARINE FISH PATHOGEN OF %VIBRIO%-%ANGUILLARUM% 775
AUTHOR: SINGER J T; SCHMIDT K A; RENO P W
AUTHOR ADDRESS: DEP. BIOCHEM., MICROBIOL. MOL. BIOL., UNIV. MAINE, ORONO, MAINE 04459.
JOURNAL: J BACTERIOL 173 (3). 1991. 1347-1352. 1991
FULL JOURNAL NAME: Journal of Bacteriology
CODEN: JOBAA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Insertions were created in three iron uptake genes in plasmid pJM1 of %Vibrio% %anguillarum% 775 to assess their in vivo effects on virulence in fish. Insertions that blocked p40, pOM2, and pAngR expression resulted in iron uptake-negative strains and in 4.2 .times. 105-, 8.8 .times. 105-, and 2.5 .times. 105-fold attenuations in virulence, respectively. A strain with an insertion in the pAngR coding region still synthesized significant constitutive levels of the outer membrane protein pOM2 and persisted in fish for at least 14 days postinjection. The results demonstrate a direct relationship between virulence and three pJM1-encoded gene products and also the feasibility of constructing live %attenuated% strains of V. anguillarum that might be useful in future %vaccines%.

1991

7/3,AB/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06728939 BIOSIS NO.: 000088038365
PROTECTION OF RAINBOW TROUT VIBRIOSIS AND FURUNCULOSIS BY THE USE OF %ATTENUATED% STRAINS OF %VIBRIO%-%ANGUILLARUM%
AUTHOR: NORQVIST A; HAGSTROM A; WOLF-WATZ H
AUTHOR ADDRESS: DEP. MICROBIOL., UNIV. UMEA, S-901 87 UMEA, SWED.
JOURNAL: APPL ENVIRON MICROBIOL 55 (6). 1989. 1400-1405. 1989
FULL JOURNAL NAME: Applied and Environmental Microbiology
CODEN: AEMID
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The fish pathogen Vibro anguillarum causes a lethal infection in rainbow trout (Salmo gairdneri). Three different avirulent mutants, constructed by transposon insertion mutagenesis (VAN20 and VAN70) or as antibiotic-resistant mutants (VAN1000), were isolated by screening 200 individual isolated mutants for avirulence. When used as live %vaccines%, all three avirulent mutants were able to induce protective immunity

against the homologous as well as a heterologous strain of V. anguillarum. When VAN1000 was used, protective immunity could be recorded 1 week after bath vaccination with 107 bacteria per ml of water for 30 min. A single-dose immunization was effective for at least 12 weeks. Western immunoblotting showed that strains of V. anguillarum have antigenic determinants in common with Aeromonas strains. Therefore, we tested and confirmed that VAN1000 also was able to induce protective immunity against challenge with Aeromonas salmonicida.

1989

7/3,AB/5 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

05883514 Genuine Article#: XE335 Number of References: 53
Title: Immunogenicity of synthetic peptides representing antigenic determinants on the infectious hematopoietic necrosis virus glycoprotein (ABSTRACT AVAILABLE)
Author(s): Emmenegger E (REPRINT) ; Landolt M; LaPatra S; Winton J
Corporate Source: UNIV WASHINGTON,SCH FISHERIES, POB 357980/SEATTLE//WA/98195 (REPRINT); CLEAR SPRINGS FOODS INC,/BUHL//ID/83316; NW BIOL SCI CTR,/SEATTLE//WA/98115
Journal: DISEASES OF AQUATIC ORGANISMS, 1997, V28, N3 (MAR 27), P175-184
ISSN: 0177-5103 Publication date: 19970327
Publisher: INTER-RESEARCH, NORDBUNTE 23, D-21385 OLDENDORF LUHE, GERMANY
Language: English Document Type: ARTICLE
Abstract: Three peptides, P76, P226, and P268 representing 3 putative antigenic determinants on the glycoprotein of infectious hematopoietic necrosis virus (IHNV), were synthesized and injected into rainbow trout Oncorhynchus mykiss to assess their immunogenicity. Antisera extracted from the immunized trout were analyzed using an enzyme linked immunosorbent assay (ELISA) for the presence of antibodies that could bind to the peptides or to intact Virions of IHNV. The antisera were also tested for neutralizing activity against IHNV by a complement-mediated neutralization assay. In general, recognition of the peptides and IHNV was low and only a few antibody binding patterns were demonstrated. Antisera from fish injected with P76 constructs recognized the homologous peptide more than the heterologous peptides, whereas antisera from fish inoculated with either P226 or P268 constructs recognized P76 equally, or better, than the homologous peptide; however, there was a high degree of individual variation within each treatment group. Neutralization activity was demonstrated by serum from a single fish injected with one of the peptides (P268) and from 7 of 10 positive control fish infected with an %attenuated% strain of IHNV. Possible explanations for the dichotomous immune responses are discussed. These results indicate we need to improve our overall understanding of the fish immune system in order to facilitate the development of an efficacious %vaccine% against IHNV.

7/3,AB/6 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

03273375 Genuine Article#: NT165 Number of References: 41
Title: THE DEVELOPMENT OF LIVE %VACCINES% FOR FURUNCULOSIS LACKING THE A-LAYER AND O-ANTIGEN OF AEROMONAS-SALMONICIDA (Abstract Available)
Author(s): THORNTON JC; GARDUNO RA; KAY WW
Corporate Source: UNIV VICTORIA,DEPT BIOCHEM/VICTORIA V8W 3P6/BC/CANADA/; UNIV VICTORIA,CANADIAN BACTERIAL DIS NETWORK/VICTORIA V8W 2Y2/BC/CANADA/; MICROLOGIX BIOTECH INC/VICTORIA/BC/CANADA/
Journal: JOURNAL OF FISH DISEASES, 1994, V17, N3 (MAY), P195-204
ISSN: 0140-7775
Language: ENGLISH Document Type: ARTICLE
Abstract: Mutants of Aeromonas salmonicida strains lacking either the A-protein, O-antigen or both of these major surface antigens were tested in rainbow trout, Oncorhynchus mykiss (Walbaum), for their

suitability as live %vaccines% (LV). All of these mutants were shown to be %attenuated%, as fish receiving approximately 5 X 10(7) of the respective strains showed no clinical signs of furunculosis. Immersion vaccination of fish in 5 x 10(7) cfu ml-1 of these strains with an identical immersion dose 14 days later resulted in significant protection by all strains from challenge with a heterologous virulent strain of A. salmonicida 5 weeks later. The levels of protection conferred were all greater than or equal to that provided by an injected bacterin using the same vaccination schedule. With one exception, all LV strains that still possessed a functional 0-antigen provided protective indices (PI) four- to seven-fold greater than the PI for the fish injected with bacterin. When antibody responses of vaccinated fish were compared, it was found that only vaccination by bacterin gave rise to a measurable agglutinating titre. Western immunoblots using the immune fish sera failed to reveal any major differences in antigen recognition in fish that received any of the %vaccines% tested. These data suggest that the immune response generated by the use of live %vaccine% strains is different from that generated by a bacterin, and that these useful mutations may be incorporated into existing furunculosis LVs for further attenuation.

7/3,AB/7 (Item 3 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

00971116 Genuine Article#: FK459 Number of References: 29
Title: COMPARISON OF REPRESENTATIVE STRAINS OF INFECTIOUS HEMATOPOIETIC NECROSIS VIRUS BY SEROLOGICAL NEUTRALIZATION AND CROSS-PROTECTION ASSAYS (Abstract Available)
Author(s): ENGELKING HM; HARRY JB; LEONG JAC
Corporate Source: OREGON STATE UNIV,DEPT MICROBIOL/CORVALLIS//OR/97331; OREGON STATE UNIV,DEPT MICROBIOL/CORVALLIS//OR/97331; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL &IMMUNOL/LOS ANGELES//CA/90024
Journal: APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1991, V57, N5, P1372-1378
Language: ENGLISH Document Type: ARTICLE
Abstract: Infectious hematopoietic necrosis virus (IHNV) is a pathogen of young salmon and trout. Viral epizootics among these fish in private and public rearing facilities have been a problem in the northwestern United States from California to Alaska, and an IHNV %vaccine% has been sought by the aquaculture experts. Since an IHNV %vaccine% must be designed to immunize against all viral serotypes, an analysis of IHNV serotypes was made. A large number of viruses from widely separated geographic locations and different fish species had already been placed in one of five electropherotypes by the migration of the virion proteins in sodium dodecyl sulfate-polyacrylamide gels. Also, there was evidence that some of these virus isolates had differences in virulence for chinook salmon, rainbow trout, or kokanee salmon. Previous serological studies with polyclonal rabbit antisera and three IHNV isolates indicated that there was only one serotype (B. B. McCain, J. L. Fryer, and K. S. Pilcher, Proc. Soc. Exp. Biol. Med. 137:1042-1046, 1971). A substantial number of new IHNV isolations have been made since that study, and thus a more extensive comparison was made of 10 different IHNV isolates representing the five electropherotypes. This report shows that the glycoprotein from a single isolate of IHNV can induce a protective immune response in vivo to the five IHNV electropherotypes. Plaque reduction neutralization assays indicated that there was only one serotype. Thus, despite the differences observed in the migration of the structural proteins for IHNV isolated from separate geographic locations and different fish species, only one neutralizing virus type was identified.

7/3,AB/8 (Item 1 from file: 50)
DIALOG(R)File 50:CAB Abstracts

03048602 CAB Accession Number: 952210970
A field trial with the live %attenuated% fish %vaccine% strain %Vibrio%

(Listonella) %anguillarum% VAN10[redacted]
Norqvist, A.; Bergman, A.; Skogman, G.; Wolf-Watz, H.
Department of Microbiology, National Defence Research Establishment, S-901 82 Umea, Sweden.
Bulletin of the European Association of Fish Pathologists vol. 14 (5): p.156-158
Publication Year: 1994
ISSN: 0108-0288 --
Language: English
Document Type: Journal article
The %attenuated% live %vaccine% strain V. anguillarum VAN 1000 was tested in a small-scale vaccination field trial. During an outbreak of vibriosis in the Baltic Sea, 68% of unvaccinated rainbow trout died while only 14% of the vaccinated rainbow trout died. 10 ref.

7/3,AB/9 (Item 2 from file: 50)
DIALOG(R)File 50:CAB Abstracts

02375178 CAB Accession Number: 912218891
Polypeptides p40, pOM2, are required for iron uptake and for virulence of the marine fish pathogen %Vibrio% %anguillarum% 775.
Singer, J. T.; Schmidt, K. A.; Reno, W.
Department of Biochemistry, Microbiology, and Molecular Biology, University of Maine, Orono, ME 04469, USA.
Journal of Bacteriology vol. 173 (3): p.1347-1352
Publication Year: 1991
ISSN: 0021-9193 --
Language: English
Document Type: Journal article
Insertions were created in three iron uptake genes in plasmid pJM1 of V. anguillarum 775 to assess their in vivo effects on virulence in fish. Insertions that blocked p40, pOM2, and pAngR expression resulted in iron uptake-negative strains and in 4.2x105, 8.8x105, and 2.5x105-fold attenuations in virulence, respectively. A strain with an insertion in the pAngR coding region still synthesized significant constitute levels of the outer membrane protein pOM2 and persisted in fish for at least 14 days after injection. The results show a direct relationship between virulence and three pJM1-encoded gene products and also the feasibility of constructing live %attenuated% strains of V. anguillarum that might be useful in future %vaccines%. 38 ref.

7/3,AB/10 (Item 3 from file: 50)
DIALOG(R)File 50:CAB Abstracts

02138650 CAB Accession Number: 892293115
Protection of rainbow trout against vibrosis and furunculosis by the use of %attenuated% strains of %Vibrio% %anguillarum%.
Norqvist, A.; Hagstrom, A .; Wolf-Watz, H.
Dep. Microbiol., Univ., 901 87 Umea , Sweden.
Applied and Environmental Microbiology vol. 55 (6): p.1400-1405
Publication Year: 1989
ISSN: 0099-2240 --
Language: English
Document Type: Journal article
Three different avirulent mutants, contructed by transposon mutagenesis (VAN20 and VAN70) or as antibiotic-resistant mutants (VAN1000), were isolated by screening 200 individual isolated mutants for avirulence. When used as live %vaccines%, all three avirulent mutants induced protective immunity against the homologous as well as a heterologous strains of V. anguillarum. When VAN1000 was used, protective immunity was detected 1 week after bath vaccination with 107 bacteria/ml of water for 30 minutes. A single-dose immunization was effective for at least 12 weeks. Western immunoblotting showed that strains of V. anguillarum have antigenic determinants in common with Aeromonas strains. It was confirmed that VAN1000 also induced protective immunity against challenge with Aeromonas

salmonicida. 20 ref.

7/3,AB/11 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

06080823 EMBASE No: 1995111310
Vaccination in European salmonid aquaculture: A review of practices and prospects
Press McL. C.; Lillehaug A.
Department Morphology, Box 8146 Dep, Genetics and Aquatic Biology, Norwegian Coll. Veterinary Medicine,0033 Oslo Norway
British Veterinary Journal (BR. VET. J.) (United Kingdom) 1995, 151/1 (45-69)
CODEN: BVJOA ISSN: 0007-1935
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Disease control by vaccination is widely used in European salmonid aquaculture against vibriosis (%Vibrio% %anguillarum%), cold-water vibriosis (Vibrio salmonicida), yersiniosis or enteric redmouth disease (Yersinia ruckeri) and furunculosis (Aeromonas salmonicida subsp. salmonicida). The %vaccines% against the Vibrio spp. and Y. ruckeri have proven effective especially when administered by injection. Furunculosis %vaccines% have been less successful and have relied on combination with potent adjuvants to achieve acceptable protection. Application of modern molecular techniques to furunculosis research has delivered a crop of experimental %vaccines% that incorporate purified virulence factors and have shown increased protection during challenge. Gene technology has also been used to create a defined, non-reverting mutation in a strain of A. salmonicida, which has enhanced the feasibility of %attenuated% live %vaccines%. The development of experimental subunit %vaccines% against the viral infections and the continued advances in the field of immunostimulants, adjuvants and antigen carriers provide considerable promise for the future development of commercial %vaccines% for use in salmonid aquaculture.

7/3,AB/12 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00985479
SUB-UNIT %VACCINE% FOR INFECTIOUS PANCREATIC NECROSIS VIRUS
VACCIN SOUS-UNITE POUR LE VIRUS DE NECROSE PANCREATIQUE INFECTIEUX
Patent Applicant/Assignee:
UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE, Office of Research Administration/Tech. Dev., 701 E. Pratt Street, Suite 200, Baltimore, MD 21202, US, US (Residence), US (Nationality)
Inventor(s):
VAKHARIA Vikram N, 7906 Oxfarm Court, Bowie, MD 20715, US,
Legal Representative:
FUIERER Marianne (et al) (agent), Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200313597 A1 20030220 (WO 0313597)
Application: WO 2002US25185 20020812 (PCT/WO US0225185)
Priority Application: US 2001311488 20010810
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English

Fulltext Word Count: 8760

English Abstract
The present invention relates to sub-unit %vaccines% comprising structural polypeptides of Infectious Pancreatic Necrosis Virus (IPNV) comprising structural proteins V2 and V3 folded as empty IPNV viral capsid that approximates the size and structural conformation of native IPNV virus.

French Abstract
L'invention se rapporte a des vaccins sous-unite contenant des polypeptides structurels du Virus de necrose pancreatique infectieux (IPNV) comprenant des proteines structurelles V2 et V3 pliees en tant que capsides virales du IPNV qui avoisine la taille et la conformation structurelle du virus IPNV natif.

7/3,AB/13 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00972157
WHITE SPOT SYNDROME VIRUS %VACCINE%
VACCIN CONTRE LE VIRUS DE LA MALADIE DU POINT BLANC
Patent Applicant/Assignee:
AKZO NOBEL N V, Velperweg 76, NL-6824 BM Arnhem, NL, NL (Residence), NL (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
VAN HULTEN Maria Cornelia Wilhelmina, Salverdaplein 10, NL-6701 DB Wageningen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
VLAK Justinus Maria, Nieuwe Veenendaalseweg 214, NL-3911 MR Rhenen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
Legal Representative:
KEUS J A R (agent), P.O. Box 31, NL-5830 AA Boxmeer, NL,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200300900 A1 20030103 (WO 0300900)
Application: WO 2002EP6746 20020618 (PCT/WO EP0206746)
Priority Application: NL 1202418 20010622
Designated States: AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MD MG MK MN MX NO NZ PH PL RO RU SD SG SI SK TR TT UA US UZ VN YU ZA
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 7315

English Abstract
The present invention relates i.a. to nucleic acid sequences encoding a novel WSSV protein. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acid sequences, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences. The invention also relates to %vaccines% for combating WSSV infections, to methods for the preparation thereof and to the use of such proteins for the manufacturing of such %vaccines%. Finally the invention relates to diagnostic tests for the detection of WSSV antigenic material.

French Abstract
L'invention concerne, entre autres, des sequences nucleotidiques codant pour une nouvelle proteine WSSV. Elle porte egalement sur des fragments d'ADN, sur des molecules d'ADN recombinees et sur des vehicules recombines vivants comprenant lesdites sequences. Elle se rapporte encore a des cellules hotes comprenant lesdites sequences nucleotidiques, lesdits fragments d'ADN, lesdites molecules d'ADN recombinees et lesdits

vehicules recombines vivants. El[redacted] concerne des proteines codees [redacted]r lesdites sequences nucleotidiques, des vaccins pour combattre les infections a WSSV, leurs methodes de preparation et l'utilisation desdites proteines pour la fabrication desdits vaccins. Elle porte enfin sur des essais diagnostiques pour la detection de materiel antigenique WSSV.

7/3,AB/14 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00946669
NUCLEIC ACIDS ENCODING ISAV POLYPEPTIDES
ACIDES NUCLEIQUES CODANT POUR DES POLYPEPTIDES DU VIRUS DE L'ANEMIE INFECTIEUSE DU SAUMON
Patent Applicant/Assignee:
MICROTEK INTERNATIONAL LTD, 6761 Kirkpatrick Crescent, Victoria, British Columbia V8X 3X1, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
CLOUTHIER Sharon C, RR 3, Box 1560, Holden, ME 04429, US, US (Residence), CA (Nationality), (Designated only for: US)
ANDERSON Eric D, RR 3, Box 1560, Holden, ME 04429, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
POLLEY Richard J (agent), Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 S.W. Salmon Street, Portland, OR 97204, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200279231 A2 20021010 (WO 0279231)
Application: WO 2002US9681 20020329 (PCT/WO US0209681)
Priority Application: US 2001280545 20010330
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 13858

English Abstract
Infectious Salmon Anemia Virus (ISAV) nucleic acid molecules and polypeptides are disclosed, as well as host cells and transgenic fish transformed by expression vectors containing such nucleic acids. The nucleic acid molecules can encode antigenic epitopes capable of eliciting an immune response in a host cell or animal, such as an immune response against ISAV, and the polypeptides themselves can be antigenic epitopes and also induce such an immune response.

French Abstract
L'invention concerne des molecules d'acides nucleiques du virus de l'anemie infectieuse du saumon (ISAV) et des polypeptides, ainsi que des cellules hotes et des poissons transgeniques transformes au moyen de vecteurs d'expression contenant lesdits acides nucleiques. Lesdites molecules d'acides nucleiques peuvent coder pour des epitopes antigenes capables de stimuler une reponse immunitaire dans une cellule hote ou chez un animal, telles qu'une reponse immunitaire a l'encontre d'ISAV, et les polypeptides peuvent eux-memes etre des epitopes antigenes et induire egalement cette reponse immunitaire.

7/3,AB/15 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00937679
NUCLEIC ACIDS FOR TRANSFORMING FISH CELLS AND METHODS FOR THEIR USE
ACIDES NUCLEIQUES DE TRANSFORMATION DE CELLULES DE POISSONS ET LEURS METHODES D'UTILISATION

Patent Applicant/Assignee:
THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of OREGON STATE UNIVERSITY, Office of Technology Transfer, 312 Kerr Administration Building, Corvallis, OR 97331-2140, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
ALONSO Marta, 3265 Orchard Avenue, Corvallis, OR 97331, US, US (Residence), ES (Nationality), (Designated only for: US)
CHIOU Pinwen P, Storrs, CT, US, US (Residence), -- (Nationality), (Designated only for: US)
LEONG Jo-Ann C, 879 Independence Highway, Albany, OR 97321, US, US (Residence), US (Nationality), (Designated only for: US)
JOHNSON Marc C, Ithaca, NY, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
POLLEY Richard J (agent), Klarquist, Sparkman LLP, Suite 1600, One World Trade Center, 121 SW Salmon Street, Portland, OR 97204, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200269840 A2 20020912 (WO 0269840)
Application: WO 2002US6738 20020304 (PCT/WO US0206738)
Priority Application: US 2001273584 20010305
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 16894

English Abstract
A nucleic acid sequence, the rainbow trout interferon regulatory factor-1 (IRF1A) promoter, is disclosed. This promoter is capable of expressing a nucleic acid sequence operably linked to it in fish cells. IRF1A can be operably linked to antigenic sequences for fish or shellfish pathogens, thus inducing an immune response in a fish transformed with such a nucleic acid. Some of the vectors described utilize a nucleic acid containing an inducible promoter operably linked to a nucleic acid sequence encoding a polypeptide capable of inducing programmed cell death (PCD).

French Abstract
L'invention concerne une sequence d'acides nucleiques, le promoteur (IRF1A) du facteur 1 regulateur d'interferons chez la truite arc-en-ciel. Ce promoteur peut exprimer une sequence d'acides nucleiques liee de maniere fonctionnelle audit promoteur dans les cellules de poissons. IRF1A peut etre lie de maniere fonctionnelle a des sequences antigeniques d'agents pathogenes de poissons ou de mollusques et de crustaces, ce qui permet d'induire une reponse immunitaire chez un poisson transforme par un tel acide nucleique. Certains de ces vecteurs susmentionnes utilisent un acide nucleique contenant un promoteur inductible lie fonctionnellement a une sequence d'acides nucleiques qui code un polypeptide capable d'induire la mort cellulaire programmee.

7/3,AB/16 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00907737
EXOENZYME TOXIN OF AEROMONAS SALMONICIDA, AND USES THEREOF

TOXINE EXOENZYME D'AEROMONAS SALMONICIDA, ET UTILISATIONS ASSOCIEES
Patent Applicant/Inventor:
FREY Joachim, Schreinerweg 9, CH-3012 Bern, CH, CH (Residence), CH (Nationality)
KUHNERT Peter, Bahnhofstrasse 1, CH-3315 Baetterkinden, CH, CH (Residence), CH (Nationality)
BRAUN Martin, Ammannstmatt 69, CH-6300 Zug, CH, CH (Residence), CH (Nationality)
THORNTON Julian C, 1219 Oscar Street, Victoria, British Columbia V8V 2X6, CA, CA (Residence), CA (Nationality)
KUZIK Michael A, 1535 Jubilee Avenue #303, Victoria, British Columbia V8R 4N4, CA, CA (Residence), CA (Nationality)
BURIAN Jan, 1732 Newton Street #80, Victoria, British Columbia V8R 2R2, CA, CA (Residence), CA (Nationality)
Legal Representative:
ARRIGAR Robert H (agent), Barrigar Intellectual Property Group, Suite 830, Oceanic Plaza, 1066 West Hastings Street, Vancouverm British Columbia V6E 3X1, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200240515 A2-A3 20020523 (WO 0240515)
Application: WO 2001CA1600 20011115 (PCT/WO CA0101600)
Priority Application: US 2000248864 20001115
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 10616

English Abstract
A protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin %vaccines% based on AexT for inducing immunity against A. salmonicida infections.

French Abstract
L'invention concerne une toxine proteique, denommee exoenzyme T d'Aeromonas salmonicida (AexT), appartenant a la famille des toxines ADP-ribosylantes, ainsi qu'un promoteur a dependance calcique (ou de la concentration d'un autre cation) d'A. salmonicida. Elle concerne aussi des techniques de diagnostic, de soins et de prevention, y comprise la preparation de vaccins traditionnel, recombinant et bacterien ameliore, bases sur AexT afin d'induire une immunite contre des infections par A. salmonicida.

7/3,AB/17 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00905976
YEAST DERIVED %VACCINE% AGAINST IPNV
VACCIN DERIVE DE LA LEVURE CONTRE LA NPI
Patent Applicant/Assignee:
THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, Regent Walk, Aberdeen, Grampian AB24 3FX, GB, GB (Residence), GB (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MELVIN William Thomas, 5 Deeside Park, Aberdeen, Grampian AB15 7PQ, GB, GB (Residence), GB (Nationality), (Designated only for: US)
BREEMAN Suzanne, 4 Portsoy Crescent, Ellon, Aberdeenshire AB41 8AL, GB, GB (Residence), GB (Nationality), (Designated only for: US)

LABUS Marie Beagley, 21 Wilson Place, Kemnay, Inverurie, Grampian AB51 5QN, GB, GB (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
KREMER Simon M (et al) (agent), Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200238770 A1 20020516 (WO 0238770)
Application: WO 2001GB4986 20011112 (PCT/WO GB0104986)
Priority Application: GB 200027644 20001111; GB 200030765 20001214
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 13471

English Abstract
Disclosed are processes for producing a %vaccine% for use against infectious pancreatic necrosis virus (IPNV) in fish, which process comprises culturing a yeast host cell which expresses, and preferably secretes, an IPNV polypeptide, and formulating the polypeptide as a %vaccine% (preferably by using, or partially purifying) the supernatant. Such %vaccines% have advantages over %vaccines% produced in bacteria. Also disclosed are %vaccines% based VP3 and VP2var proteins, optionally in combination with antigens protective against other fish diseases. The invention further provides related materials (e.g. primers, vectors and host cells) and methods and uses of the %vaccines% for prophylaxis and therapy.

French Abstract
L'invention concerne des processus de production d'un vaccin pouvant etre utilise contre le virus de la necrose pancreatique infectieuse (NPI) chez le poisson, processus consistant a cultiver une cellule hote de levure qui exprime, et de preference secrete, un polypeptide du virus NPI, et a preparer le polypeptide comme vaccin (en utilisant de preference, ou en purifiant partiellement, le supernageant). De tels vaccins presentent des avantages par rapport aux autres vaccins produits dans des bacteries. L'invention concerne egalement des vaccins a base de proteines VP3 et VP2var, associes de maniere facultative a des antigenes protecteurs contre d'autres maladies du poisson. L'invention concerne encore des materiaux associes (par exemple des amorces, des vecteurs et des cellules hotes), des procedes et des utilisations de ces vaccins dans la prophylaxie et le traitement.

7/3,AB/18 (Item 7 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00890012
ANTIGENIC PROTEINS OF SHRIMP WHITE SPOT SYNDROME VIRUS AND USES THEREOF
PROTEINES ANTIGENIQUES DU VIRUS DE LA MALADIE DU POINT BLANC (WSSV) DE LA CREVETTE ET UTILISATIONS DE CES PROTEINES
Patent Applicant/Assignee:
AKZO NOBEL N V, Velperweg 76, NL-6824 BM Arnhem, NL, NL (Residence), NL (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
VLAK Justinus Maria, Nieuwe Veenendaalseweg 214, NL-3911 Mr Rhenen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
VAN HULTEN Maria Cornelia Wilhelmina, Salverdaplein 10, NL-6701 DB Wageningen, NL, NL (Residence), NL (Nationality), (Designated only for: US)
Legal Representative:
KEUS Jacobus A R (agent), P.O. Box 20, NL-5340 BH Oss, NL,

Patent and Priority Information (Country, Number, Date):
  Patent: WO 200222664 A2 20020321 (WO 0222664)
  Application: WO 2001EP10679 20010914 (PCT/WO EP0110679)
  Priority Application: EP 2000203186 20000915
Designated States: AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PH PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA
  (EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
  (OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
  (AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
  (EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 6481

English Abstract
The present invention relates to antigenic proteins derived from White Spot Syndrome virus having an estimated size of 19 kDa (VP 19) or 13 kDA (VP13), to the use of these proteins in %vaccines% and to %vaccines% on the basis of these proteins. Furthermore, the invention relates to antibodies against these proteins and to the use of antibodies in %vaccines%, to nucleic acid sequences encoding these proteins and to their use in %vaccines%. Also, the invention relates to the use of said proteins in the manufacture of a %vaccine% for prophylaxis and/or treatment of White Spot Syndrome in crustaceans, to vector %vaccines% and to diagnostic kits comprising said nuclei acids or antibodies.

French Abstract
L'invention concerne des proteines antigeniques derivees du virus de la maladie du point blanc, possedant une taille estimee de 19 kDa (VP 19) ou 13 kDA (VP13), l'utilisation de ces proteines dans des vaccins et des vaccins a la base de ces proteines. L'invention concerne egalement des anticorps contre ces proteines et l'utilisation d'anticorps dans des vaccins, des sequences d'acide nucleique codant pour ces proteines ainsi que leur utilisation dans des vaccins. L'invention concerne egalement l'utilisation desdites proteines dans la fabrication d'un vaccin pour la prophylaxie et/ou le traitement de la maladie du point blanc chez les crustacees, des vaccins vecteurs ainsi que des kits de diagnostic comprenant lesdits acides nucleiques ou anticorps.

7/3,AB/19 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00867846
METHODS AND COMPOSITIONS FOR DEVELOPING SPORE DISPLAY SYSTEMS FOR MEDICINAL AND INDUSTRIAL APPLICATIONS
PROCEDES ET COMPOSITIONS PERMETTANT DE DEVELOPPER DES SYSTEMES DE PRESENTATION DE SPORES POUR DES APPLICATIONS MEDICINALES ET INDUSTRIELLES
Patent Applicant/Assignee:
  MAXYGEN INC, 515 Galveston Drive, Redwood City, CA 94063, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
  GOLDMAN Stanley, 760 Rosewood Drive, Walnut Creek, CA 94596, US, US (Residence), US (Nationality), (Designated only for: US)
  LATHROP Stephanie J, Building J-2079, 1000 Escalon Drive, Sunnyvale, CA 94085, US, US (Residence), AU (Nationality), (Designated only for: US)
  LONGCHAMP Pascal F, 1866 West Bayshore Road, #B, East Palo, CA 94303, US, US (Residence), CH (Nationality), (Designated only for: US)
  WHALEN Robert G, 1200 East Hillsdale Boulevard, #108, Foster City, CA 94404, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
  BASTIAN Kevin L (agent), Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111-3834, US,
Patent and Priority Information (Country, Number, Date):
  Patent: WO 200200232 A2-A3 20020103 (WO 0200232)
  Application: WO 2001US20372 20010626 (PCT/WO US0120372)

Priority Application: US 2000214[illegible] 20000626
Designated States: AE AG AL AM AT AT (utility model) AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ (utility model) DE DE (utility model) DK DK (utility model) DM DZ EC EE EE (utility model) ES FI FI (utility model) GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK (utility model) SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 43437

English Abstract
Compositions and methods for utilizing spore systems for medicinal and industrial protein applications are provided. Compositions comprise spores that produce and/or display carbohydrates, proteins, and nucleic acids of interest. Such spores are useful as therapeutic or prophylactic agents or %vaccines% against a broad spectrum of immunogens and bacterial and viral pathogens. Additionally, spore systems are useful in production, packaging, delivery, and presentation of polypeptides and/or nucleic acids for industrial catalysts, medical applications, and diagnostic applications.

French Abstract
L'invention concerne des compositions et des procedes d'utilisation de systemes de spores dans des applications proteiniques medicinales et industrielles. Les compositions contiennent des spores qui produisent et/ou presentent des glucides, des proteines, des peptides et des acides nucleiques interessants. Ces spores sont utiles comme agents therapeutiques ou prophylactiques ou comme vaccins contre un large eventail d'immunogenes et d'agents pathogenes bacteriens et viraux. Les systemes de spores sont, en outre, utiles dans la production, l'encapsidation, la fourniture et la presentation de polypeptides et/ou d'acides nucleiques pour des catalyseurs industriels, des applications medicales et diagnostiques.

7/3,AB/20 (Item 9 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00834398
THERAPEUTIC AND PROPHYLACTIC AGENTS DERIVED FROM AEROMONAS HYDROPHILA BACTERIAL SURFACE PROTEINS
AGENTS THERAPEUTIQUES ET PROPHYLACTIQUES DERIVES DES PROTEINES DE SURFACES BACTERIENNES AEROMONAS HYDROPHILA
Patent Applicant/Assignee:
THE NATIONAL UNIVERSITY OF SINGAPORE, 10 Kent Ridge Crescent, Singapore 119260, SG, SG (Residence), SG (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
SIN Yoke Min, Industry & Technology Relations Office, Innovation House, 8 Prince George's Park, Singapore 118407, SG, SG (Residence), SG (Nationality), (Designated only for: US)
GE Ruowen, Industry & Technology Relations Office, Innovation House, 8 Prince George's Park, Singapore 118407, SG, SG (Residence), CN (Nationality), (Designated only for: US)
FANG Haoming, Industry & Technology Relations Office, Innovation House, 8 Prince George's Park, Singapore 118407, SG, SG (Residence), CN (Nationality), (Designated only for: US)
Legal Representative:
SACHITHANANTHAN Suresan (agent), Tan Rajah & Cheah, 9 Battery Road #15-00, Straits Trading Building, Singapore 049910, SG,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200166571 A1 20010913 (WO 0166571)
Application: WO 2001SG29 20010307 (PCT/WO SG0100029)

Priority Application: SG 20001261 20000308
Designated States: CA NO US
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
Publication Language: English
Filing Language: English
Fulltext Word Count: 26178

English Abstract
The invention provides a novel surface polypeptide from Aeromonas hydrophila as well as fragments, variants and derivatives of this polypeptide. Also provided are polynucleotides encoding the polypeptide, fragments, variants and derivatives. Compositions containing the polypeptide and polynucleotides of the invention are also disclosed as well as methods useful in the treatment and prevention of bacterial infection in an animal, wherein said infection is caused by bacteria of a genus selected from the group consisting of Aeromonas, Vibrio and Edwardsiella, and in the diagnosis of bacterial infection in an animal, wherein said infection is caused by bacteria of a genus Aeromonas.

French Abstract
L'invention concerne un nouveau polypeptide de surface provenant de l'Aeromonas hydrophila ainsi que des fragments, des variantes et des derives de ce polypeptide. L'invention traite aussi de polynucleotides codant le polypeptide, des fragments, des variantes et des derives. L'invention a pour objet egalement des compositions contenant le polypeptide et les polynucleotides selon l'invention, ainsi que des procedes permettant de traiter et de prevenir l'infection bacterienne chez l'animal, lorsque ladite infection est provoquee par des bacteries du genre selectionne dans le groupe se composant d'Aeromonas, Vibrio et Edwardsiella. En outre, ces procedes permettent de diagnostiquer l'infection bacterienne chez l'animal, lorsque ladite infection est provoquee par les bacteries du genre Aeromonas.

7/3,AB/21 (Item 10 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00822772
%VACCINE% COMPOSITION, PROCESS AND METHODS
COMPOSITION DE VACCIN, PROCEDE ET METHODES
Patent Applicant/Inventor:
JIRA Vic, 5347 Peck Road, Unit D, El Monte, CA 91732, US, US (Residence), US (Nationality)
JIRATHITICAL Vichai, 71 Moo, 5 Bangpagong Industrial Park, 1 Takarm Bangpagong, 24130 Chachoengsao, TH, TH (Residence), TH (Nationality)
Patent and Priority Information (Country, Number, Date):
Patent: WO 200154717 A1 20010802 (WO 0154717)
Application: WO 2001US2811 20010129 (PCT/WO US0102811)
Priority Application: US 2000494607 20000131; US 2000227520 20000824
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 28628

English Abstract
A %vaccine% composition for treating or preventing pathogen-induced infections, malignant diseases, and immune disorders, i.e., inflammation and autoimmune diseases, is disclosed, along with a process for manufacturing the composition and various methods of using the composition. The composition comprises pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which are

reduced and/or denatured. The preferred composition is administer across the mucosal surface of a subject suffering or about to suffer from infection, tumor, or immune disease. The composition is administered as a preventive or a therapeutic %vaccine%.

French Abstract
L'invention concerne une composition de vaccin destinee au traitement ou a la prevention d'infections induites par des agents pathogenes, d'affections malignes, et de troubles immunitaires, c'est-a-dire, des inflammations et des maladies autoimmunes. L'invention concerne egalement un procede de fabrication de cette composition et plusieurs methodes d'utilisation de cette composition. Cette composition comprend une cellule ou un tissu infecte par des agents pathogenes, ou des cellules ou des tissus devenus malins ou immunologiquement aberrants, reduits et/ou denatures. La composition preferee est administree a travers la muqueuse d'un patient atteint ou sur le point d'etre atteint d'une infection, d'une tumeur, ou d'une maladie immune. Cette composition est administree comme vaccin preventif ou therapeutique.

7/3,AB/22 (Item 11 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00532472
CONTROL OF PARASITIC INFESTATIONS IN FARMED AND WILD FISH
LUTTE CONTRE LES INFESTATIONS PARASITAIRES DES POISSONS D'ELEVAGE OU SAUVAGES
Patent Applicant/Assignee:
ALPHARMA AS,
JENSEN Lone Pia,
ALEXANDERSEN Svein,
EVENSEN Oystein,
SYVERTSEN Christian,
MARTINSEN Bernt,
Inventor(s):
ALEXANDERSEN Svein,
EVENSEN Oystein,
SYVERTSEN Christian,
MARTINSEN Bernt,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9963824 A2 19991216
Application: WO 99IB966 19990531 (PCT/WO IB9900966)
Priority Application: NO 982650 19980609
Designated States: AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 9719

English Abstract
A method to control parasitic infestations including infestations with sea lice and isopod species in farmed fish in which antiparasitically active substances are formulated as an injectable composition, optionally in a fish %vaccine% and where the antiparasitically active substances also protect the fish against parasites for a substantial period of time after injection. A composition for therapeutic and prophylactic control of parasites in farmed and wild fish comprising hexaflumuron or other chitin synthesis inhibitors as the active substance is also described. Hexaflumuron can be administered as a bath treatment, orally through the feed, or as separate injections. The composition has a therapeutic effect against parasites that are already present on the fish and confers protection against new parasitic infestation for an extended period of time after treatment.

French Abstract

L'invention concerne un procede de lutte contre les infestations parasitaires, y compris des infestations de poissons d'elevage par le poux de poisson et des especes isopodes. Selon le procede, des substances ayant une activite antiparasitaire sont preparees comme composition injectable, eventuellement dans vaccin pour poisson, pour proteger des poissons contre les parasites pendant une duree prolongee apres injection. On decrit une composition qui s'utilise a des fins therapeutiques ou prophylaxiques pour lutter contre les infestations parasitaires des poissons d'elevage ou sauvages. Cette composition contient de l'hexaflumuron ou autres inhibiteurs de la synthese de chitine comme principe actif. L'hexaflumuron peut etre administre comme traitement de bain, par voie orale melange a l'alimentation, ou sous forme d'injections separees. La composition a un effet therapeutique contre les parasites deja presents sur des poissons, et confere une protection contre de nouvelles infestations parasitaires pendant une duree prolongee apres traitement.

7/3,AB/23 (Item 12 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00519067
A METHOD FOR GENERATING NONPATHOGENIC, INFECTIOUS PANCREATIC NECROSIS VIRUS (IPNV) FROM SYNTHETIC RNA TRANSCRIPTS
PROCEDE DE GENERATION DE VIRUS DE NECROSE PANCREATIQUE INFECTIEUX, NON PATHOGENE, VIVANT (IPNV) A PARTIR DE PRODUITS DE TRANSCRIPTION D'ARN SYNTHETIQUE
Patent Applicant/Assignee:
UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,
VAKHARIA Vikram N,
YAO Kun,
Inventor(s):
VAKHARIA Vikram N,
YAO Kun,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9950419 A2 19991007
Application: WO 99US4285 19990331 (PCT/WO US9904285)
Priority Application: US 9880178 19980331
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 14518

English Abstract
A system for the generation of live, nonpathogenic infectious pancreatic necrosis virus (IPNV), a segmented double-stranded (ds)RNA virus of the i(Birnavirdae) family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDNA clones were constructed which contained the coding and non-coding regions of RNA segments A and B of IPNV, respectively. Segment A was modified to prevent the expression of NS protein. Synthetic RNAs of both segments were produced by i(in vitro) transcription of linearized plasmids with T7 RNA polymerase. Transfection of CHSE cells with combined plus-sense transcripts of both segments generated infectious virus. The development of a system for producing NS protein deficient IPNV will greatly facilitate studies of viral pathogenesis, and the development of live %attenuated% %vaccines% for IPNV.

French Abstract
On a mis au point un systeme permettant de generer un virus de necrose pancreatique infectieux, non pathogene, vivant (IPNV), un virus d'ARN/ds segmente, double-brin qui utilisent des produits de transcription synthetiques, derives de l'ADN clonee. On a elabore des clones d'ADNc independants, pleine longueur, contenant les regions codante et non

codante des segments d'ARN A et B respectivement, de l'IPNV. Un segment A a ete modifie pour empecher l'expression de la proteine NS. Les ARN synthetiques des deux segments ont ete produits par transcription i(in vitro) de plasmides linearises avec l'ARN-polymerase T7. La transfection de cellules CHSE avec des produits de transcription combines sens positif des deux segments a genere un virus infectieux. La mise au point d'un systeme permettant de produire un IPNV prive de proteine NS facilite considerablement les etudes sur la pathogenese virale et l'elaboration de vaccins attenues vivants pour IPNV.

7/3,AB/24 (Item 13 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00416273
NOVEL PROKARYOTIC POLYNUCLEOTIDES, POLYPEPTIDES AND THEIR USES
NOUVEAUX POLYNUCLEOTIDES ET POLYPEPTIDES PROCARYOTES ET LEURS UTILISATIONS
Patent Applicant/Assignee:
SMITHKLINE BEECHAM CORPORATION,
BLACK Michael Terence,
HODGSON John Edward,
KNOWLES David Justin Charles,
LONETTO Michael Arthur,
NICHOLAS Richard Oakley,
STODOLA Robert King,
Inventor(s):
BLACK Michael Terence,
HODGSON John Edward,
KNOWLES David Justin Charles,
LONETTO Michael Arthur,
NICHOLAS Richard Oakley,
STODOLA Robert King,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9806734 A1 19980219
Application: WO 97US14436 19970815 (PCT/WO US9714436)
Priority Application: US 9624022 19960816
Designated States: JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 176505

English Abstract
The invention provides novel polypeptides and polynucleotides encoding such polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial compounds.

French Abstract
La presente invention concerne de nouveaux polypeptides et des polynucleotides codant lesdits polypeptides, ainsi que des procedes permettant de produire ces polypeptides au moyen de techniques de recombinaison. On decrit egalement des procedes permettant d'utiliser ces polypeptides pour cribler des composes antibacteriens.

7/3,AB/25 (Item 14 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00400490
PROTEINS INVOLVED IN THE SYNTHESIS AND ASSEMBLY OF O-ANTIGEN IN PSEUDOMONAS AERUGINOSA
PROTEINES PARTICIPANT A LA SYNTHESE ET A L'ASSEMBLAGE D'UN ANTIGENE SOMATIQUE DANS PSEUDOMONAS AERUGINOSA
Patent Applicant/Assignee:
UNIVERSITY OF GUELPH,
LAM Joseph S,
BURROWS Lori,
CHARTER Deborah,

DE KIEVIT Teresa,
Inventor(s):
LAM Joseph S,
BURROWS Lori,
CHARTER Deborah,
DE KIEVIT Teresa,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9741234 A2 19971106
Application: WO 97CA295 19970430 (PCT/WO CA9700295)
Priority Application: US 9616510 19960430; US 9739473 19970227
Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 50900

English Abstract

Nucleic acid molecules encoding proteins involved in the synthesis and assembly of O-antigen in P. aeruginosa; and proteins encoded by the nucleic acid molecules are described. Methods are disclosed for detecting P. aeruginosa in a sample by determining the presence of the proteins or a nucleic acid molecule encoding the proteins in the sample.

French Abstract

L'invention, qui a trait a des molecules d'acide nucleique codant des proteines participant a la synthese et a l'assemblage d'un antigene somatique dans P. Aeruginosa, concerne aussi des proteines codees par ces molecules d'acide nucleique. Sont egalement decrites des methodes de detection de P. Aeruginosa dans un echantillon, ces methodes consistant a verifier la presence des proteines ou d'une molecule d'acide nucleique codant les proteines dans l'echantillon.

?

7/3,AB/26 (Item 15 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00362031
PRODUCTION OF 'beta'-GLUCAN-MANNAN PREPARATIONS BY AUTOLYSIS OF CELLS UNDER CERTAIN pH, TEMPERATURE AND TIME CONDITIONS
PRODUCTION DE PREPARATIONS DE 'beta'-GLYCANNE-MANNANE PAR AUTOLYSE DES CELLULES DANS CERTAINES CONDITIONS DE PH, DE TEMPERATURE ET DE TEMPS
Patent Applicant/Assignee:
CARLTON AND UNITED BREWERIES LIMITED,
WHEATCROFT Ragini,
LANGERIS Willem Hendrik,
KULANDAI Joseph,
GILBERT Robert White,
SIME Keith James,
SMITH Craig Gordon,
Inventor(s):
WHEATCROFT Ragini,
LANGERIS Willem Hendrik,
KULANDAI Joseph,
GILBERT Robert White,
SIME Keith James,
SMITH Craig Gordon,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9702356 A1 19970123
Application: WO 96AU401 19960628 (PCT/WO AU9600401)
Priority Application: AU 953982 19950705
Designated States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 8741

English Abstract
There is provided a method of production of an immunostimulatory 'beta'-glucan-mannan preparation, comprising the step of autolysis of cells of a microorganism at a pH of 5 to 6 and a temperature of 35 to 60 degreesC for 6 to 48 hours, and separating solid material from the autolysed product. The 'beta'-glucan-mannan preparation may be incorporated as a food component or be used as a pharmaceutical for treatment of conditions such as immuno-suppression, hypercholesterolaemia, hypoglycaemia and heavy metal excretion.

French Abstract
L'invention concerne un procede pour la production d'une preparation immunostimulatrice de 'beta'-glycanne-mannane, comprenant l'etape d'autolyse de cellules d'un micro-organisme a un pH de 5 a 6 et a une temperature de 35 a 60 degreesC, pendant 6 a 48 heures, et la separation de la matiere solide du produit autolyse. La preparation 'beta'-glycanne-mannane peut etre incorporee a un compose alimentaire ou etre utilisee comme produit pharmaceutique pour le traitement d'affections telles que l'immuno-suppression, l'hypercholesterolemie, l'hypoglycemie et l'excretion de metal lourd.

7/3,AB/27 (Item 16 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00261636
PHARMACEUTICAL LYSINE-CONTAINING POLYPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
COMPOSITIONS PHARMACEUTIQUES POLYPEPTIDIQUES CONTENANT DE LA LYSINE, ET LEURS PROCEDES D'UTILISATION
Patent Applicant/Assignee:

CYTOVEN INTERNATIONAL N V,
GREEN Lawrence R,
SINACKEVICH Nicolay V,
IVANOV Vadim T,
MIKHALYOVA Inessa I,
VASKOVSKY Boris V,
MIKHALTSOV Alexander N,
KHAVINSON Vladimir K,
MOROZOV Vyacheslav G,
Inventor(s):
GREEN Lawrence R,
SINACKEVICH Nicolay V,
IVANOV Vadim T,
MIKHALYOVA Inessa I,
VASKOVSKY Boris V,
MIKHALTSOV Alexander N,
KHAVINSON Vladimir K,
MOROZOV Vyacheslav G,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9409804 A1 19940511
Application: WO 93US10341 19931028 (PCT/WO US9310341)
Priority Application: US 92967633 19921028
Designated States: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 11478

English Abstract
Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R'-L-Glx-L-Glx-L-Lys-R" and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

French Abstract
Compositions pharmaceutiques et procedes destines au traitement des etats immunitaires caracterises par l'immunodeficience, l'immunodepression ou l'hyperactivite, et a la prophylaxie et au traitement des infections opportunistes associees, lesdits procedes consistant a administrer a un sujet une composition pharmaceutiquement acceptable comportant a titre d'ingredient actif des peptides repondant a la formule R'-L-Glx-L-Glx-L-Lys-R", dans laquelle Glx represente Gln ou Glu, et/ou leurs sels pharmaceutiquement acceptables.

7/3,AB/28 (Item 17 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00214138
VIBRIO CHOLERAE STRAINS DEFECTIVE IN irgA EXPRESSION, AND CHOLERA %VACCINES% DERIVED THEREFROM
SOUCHES DE VIBRIO CHOLERAE DONT LA CAPACITE D'EXPRESSION DES GENES irgA EST DEFAILLANTE ET VACCINS CONTRE LE CHOLERA DERIVES DE CES SOUCHES
Patent Applicant/Assignee:
THE GENERAL HOSPITAL CORPORATION,
PRESIDENT AND FELLOWS OF HARVARD COLLEGE,
Inventor(s):
GOLDBERG Marcia B,
CALDERWOOD Stephen B,
MEKALANOS John J,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9211354 A1 19920709
Application: WO 91US9592 19911218 (PCT/WO US9109592)
Priority Application: US 90102 19901218

Designated States: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE
Publication Language: English
Fulltext Word Count: 14929

English Abstract
A Vibrio cholerae cell harboring a mutation which inhibits or prevents expression in the cell of a functional irgA gene product; a purified preparation of such mutant cells; and a cholera %vaccine% incorporating such mutant cells.

French Abstract
L'invention se rapporte a une cellule de Vibrio cholerae abritant une mutation qui inhibe ou previent l'expression dans la cellule d'un produit genique irgA fonctionnel; a une preparation purifiee de ces cellules mutantes; ainsi qu'a un vaccin contre le cholera dans lequel sont incorporees ces cellules mutantes.

7/3,AB/29 (Item 18 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00212993
SPRAY-DRIED ANTIGENIC PRODUCTS AND METHOD OF PREPARATION
PRODUITS ANTIGENIQUES SECHES PAR PULVERISATION ET LEUR PROCEDE DE PREPARATION
Patent Applicant/Assignee:
MICROTEK RESEARCH AND DEVELOPMENT LTD,
Inventor(s):
NEWMAN Stephen G,
KAY William W,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9210208 A1 19920625
Application: WO 91CA437 19911204 (PCT/WO CA9100437)
Priority Application: US 90836 19901204
Designated States: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL NO SE
Publication Language: English
Fulltext Word Count: 3889

English Abstract
A method is described for preparing an antigenic product which incorporates exposing an aerosol of a microbial suspension to temperatures at which substantially only the heat stable components of the microbial suspension retain their immunogenic properties. More specifically, the aerosol is exposed to an elevated temperature which denatures all labile components and removes the liquid portion of the aerosol by evaporation.

French Abstract
On decrit un procede de preparation d'un produit antigenique qui consiste a soumettre un aerosol de suspension microbienne a des temperatures telles que pratiquement seuls les composants thermostables de ladite suspension conservent leur propriete immunogenes. Plus specifiquement, on soumet l'aerosol a une temperature elevee, qui denature tous les composants instables et enleve par evaporation la partie liquide de l'aerosol.

7/3,AB/30 (Item 19 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00163233
FISH %VACCINE% COMPRISING A VIRULENT, INVASIVE BACTERIUM
VACCIN POUR POISSONS COMPRENANT UNE BACTERIE ENVAHISSANTE VIRULENTE
Patent Applicant/Assignee:
SYMBICOM AKTIEBOLAG,
WOLF-WATZ Hans,
NORQUIST Anders,

HAGSTRoM Ake,
Inventor(s):
WOLF-WATZ Hans,
NORQUIST Anders,
HAGSTRoM Ake,
Patent and Priority Information (Country, Number, Date):
Patent: WO 8909616 A1 19891019
Application: WO 89DK75 19890406 (PCT/WO DK8900075)
Priority Application: DK 189788 19880407
Designated States: AT AT AU BB BE BF BG BJ BR CF CG CH CH CM DE DE DK FI FR GA GB GB HU IT JP KP KR LK LU LU MC MG ML MR MW NL NL NO RO SD SE SE SN SU TD TG US
Publication Language: English
Fulltext Word Count: 9494

English Abstract
A live %vaccine% comprising an avirulent, invasive and immunogenic strain of a fish pathogenic bacterial species is used for the immunization of fish against infectious diseases caused by fish pathogens by immersion of the fish into a suspension of the %vaccine% strain. Suitable strains for the preparation of said %vaccine% include %Vibrio% %anguillarum% strains DSM 4506, DSM 4507 and DSM 4508.

French Abstract
On utilise un vaccin vivant comprenant une souche virulente, envahissante et immunogene d'une espece bacterienne pathogene des poissons, pour l'immunisation de poissons contre des maladies infectieuses provoquees par des pathogenes des poissons, par immersion de ces derniers dans une suspension de la souche de vaccin. Les souches appropriees permettant la preparation dudit vaccin comprennent les souches %Vibrio% %anguillarum% DSM 4506, DSM 4507, DSM 4508.

7/3,AB/31 (Item 20 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00110287
FISH %VACCINES%
VACCIN UTILISABLE EN PISCICULTURE
Patent Applicant/Assignee:
BOARD REGENTS UNIV WASHINGTON,
Inventor(s):
CROSA JORGE HOMERO,
Patent and Priority Information (Country, Number, Date):
Patent: WO 8202491 A1 19820805
Application: WO 82US39 19820115 (PCT/WO US8200039)
Priority Application: US 81225764 19810116
Designated States: AU DK FI JP NO SE
Publication Language: English
Fulltext Word Count: 2752

English Abstract
Method for making a %vaccine% against %Vibrio% %anguillarum% and other closely related vibrios. Cells containing a virulence plasmid are grown under iron limitation to allow expression of the 86, 000 dalton protein OM2 present in the outer membrane of %Vibrio% %anguillarum% when the cells are grown under iron limitation. These cells, or isolated OM2, are then used as a %vaccine%.

French Abstract
Procede de fabrication d, un vaccin contre le %Vibrio% %anguillarum% et autres vibrios etroitement apparentes. Les cellules contenant un plasmide de virulence sont cultivees avec limitation au fer afin d'exprimer la proteine OM2 86000 dalton presente dans la membrane externe du %Vibrio% %anguillarum% lorsque les cellules sont cultivees sous limitation au fer. Ces cellules, ou la proteine OM2 isolee, sont ensuite utilisees a titre de vaccin.

7/3,AB/32 (Item 1 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

4760535
Derwent Accession: 2001-440933
Utility
C/ Delivery of nucleic acid into aquatic animals
Inventor: Poet, Steven E., Winterville, GA
Burnley, Victoria Vaughn, Athens, GA
Assignee: University of Georgia Research Foundation, Inc. (02), GA
Georgia, University of Research Foundation Inc (Code: 14053)
Examiner: Priebe, Scott D. (Art Unit: 166)
Assistant Examiner: Kaushal, Sumesh
Law Firm: Schwegman, Lundberg, Woessner & Kluth, P.A.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6462027	A	20021008	US 99347959	19990706
Priority				US 99347959	19990706

Fulltext Word Count: 10467
Abstract:
Disclosed are methods for delivering a preselected polypeptide into an aquatic animal by contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide encoding an immunogen, wherein the polynucleotide is operably linked to a promoter that controls the expression of the polynucleotide in the aquatic animal, and wherein expression of the polypeptide stimulates a detectable biological response in the animal. Also disclosed are methods for delivering a desired polynucleotide into an aquatic animal comprising contacting the aquatic animal with an aquatic medium containing an isolated non-infectious, non-integrating polynucleotide, wherein the polynucleotide is substantially complementary to all or a portion of a messenger RNA (mRNA) encoding a preselected polypeptide, and wherein expression of the polypeptide stimulates or represses a detectable biological response in the animal. Methods are further disclosed for delivering a preselected polynucleotide into an aquatic animal comprising contacting the aquatic animal with an aqueous medium containing an isolated non-infectious, non-integrating polynucleotide that is not in contact with a liposome or lipid carrier, wherein the polynucleotide stimulates a detectable biological response in the animal.

7/3,AB/33 (Item 2 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

4741144
Derwent Accession: 1997-108969
Utility
C/ Production of [beta]-glucan-mannan preparations by autolysis of cells under certain pH, temperature and time conditions
Inventor: Wheatcroft, Ragini, Melbourne, AU
Kulandai, Joseph, Melbourne, AU
Gilbert, Robert White, Melbourne, AU
Sime, Keith James, Melbourne, AU
Smith, Craig Gordon, Melbourne, AU
Langeris, Willem Hendrik, Melbourne, AU
Assignee: Carlton and United Breweries, Limited (03), Carlton Victoria, AU
Carlton & United Breweries Ltd, AU (Code: 14280)
Examiner: Prats, Francisco (Art Unit: 161)
Law Firm: Foley & Lardner

	Publication Number	Kind	Date	Application Number	Filing Date

Main Patent	US 6444448	A	20020903	US 98973860	19980624
PCT	WO 9702356		19970123	WO 96AU401	19960628
		371:19980624			
		102e:19980624			
Priority				AU 953982	19950705

Fulltext Word Count: 8361

Abstract:
There is provided a method of production of an immunostimulatory [beta]-glucan-mannan preparation, comprising the step of autolysis of cells of a microorganism at a pH of 5 to 6 and a temperature of 35 to 60[degree(s)] C. for 6 to 48 hours, and separating solid material roam the autolysed product.

The [beta]-glucan-mannan preparation may be incorporated as a food component or be used as a pharmaceutical for treatment of conditions such as immuno-suppression, hypercholesterolaemia, hypoglycaemia and heavy metal excretion.

7/3,AB/34 (Item 3 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

4633849
Derwent Accession: 2002-266497
Utility
C/ Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof; ADMINISTERING PEPTIDE CONTAINING GLUTAMIC ACID- OR GLUTAMINE-LYSINE AMINO ACID SEQUENCE TO TREAT BACTERIAL, VIRAL, PARASITAL, OR FUNGAL INFECTIONS; IMMUNOMODULATION IN AIDS PATIENTS
Inventor: Green, Lawrence R., Tacoma, WA
Sinackevich, Nicolay V., St. Petersburg, RU
Ivanov, Vadim T., Moscow, RU
Mikhalyova, Inessa I., Moscow, RU
Vaskovsky, Boris V., Moscow, RU
Mikhaltsov, Alexander N., St. Petersburg, RU
Khavinson, Vladimir K., St. Petersburg, RU
Morozov, Vyacheslav G., St. Petersburg, RU
Assignee: Cytran Incorporation (02), Kirkland, WA
Cytran Inc (Code: 45946)
Examiner: Davenport, Avis M. (Art Unit: 163)
Law Firm: Townsend and Townsend and Crew LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6346514	A	20020212	US 99368449	19990804
Division	US 6066622	A		US 93144779	19931028
CIP	Abandoned			US 92967633	19921028
CIP	Abandoned			US 91783517	19911028
CIP	Abandoned			US 92816205	19920102
Priority				US 99368449	19990804
				US 93144779	19931028
				US 92967633	19921028
				US 91783517	19911028
				US 92816205	19920102

Fulltext Word Count: 9277

Abstract:
Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the

formula R'-L-Glx-L-Glx-L-Lys-R" and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

7/3,AB/35 (Item 4 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

4553912
Derwent Accession: 1999-591321
Utility
C/ Method for generating nonpathogenic infectious pancreatic necrosis virus (IPNV) from synthetic RNA transcripts; PREPARING CDNA OF INFECTIOUS PANCREATIC NECROSIS VIRUS GENOME, INITIATING REPLICATION OF DS RNA IN HOST CELL USING RNA DERIVED FROM CDNA, INCUBATING HOST CELL IN CULTURE MEDIUM, AND ISOLATING LIVE, INFECTIOUS PANCREATIC NECROSIS VIRUS
Inventor: Vakharia, Vikram N., Bowie, MD
Yao, Kun, College Park, MD
Assignee: University of Maryland-Biotechnology Institute (02), College Park, MD
Maryland, University of (Code: 52744)
Examiner: Mosher, Mary E. (Art Unit: 168)
Law Firm: Arent Fox Plotkin Kintner Kahn PLLC.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6274147	A	20010814	US 99282147	19990331
Priority				US 99282147	19990331
Provisional				US 60-80178	19980331

Fulltext Word Count: 11511

Abstract:
A system for the generation of live, nonpathogenic infectious pancreatic necrosis virus (IPNV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDNA clones were constructed which contained the coding and non-coding regions of RNA segments A and B of IPNV, respectively. Segment A was modified to prevent the expression of NS protein. Synthetic RNAs of both segments were produced by in vitro transcription of linearized plasmids with T7 RNA polymerase. Transfection of CHSE cells with combined plus-sense transcripts of both segments generated infectious virus. The development of a system for producing NS protein deficient IPNV will greatly facilitate studies of viral pathogenesis, and the development of live %attenuated% %vaccines% for IPNV.

7/3,AB/36 (Item 5 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

4324933
Derwent Accession: 2000-410680
Utility
C/ Immunomodulating peptides and methods of use; ADMINISTERING PENTAPEPTIDE
Inventor: Green, Lawrence R., Tacoma, WA
Sinackevich, Nicolay V., St. Petersburg, RU
Ivanov, Vadim T., Moscow, RU
Mikhalyova, Inessa I., Moscow, RU
Vaskovsky, Boris V., Moscow, RU
Mikhaltsov, Alexander N., St. Petersburg, RU
Khavinson, Vladimir K., St. Petersburg, RU
Morozov, Vyacheslav G., St. Petersburg, RU
Assignee: Cytran, Inc. (02), Kirkland, WA
Cytran Inc (Code: 45946)
Examiner: Davenport, Avis M. (Art Unit: 164)

Law Firm: Townsend and Townsend and Crew

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6066622	A	20000523	US 93144779	19931028
CIP	Pending			US 92967633	19921028
	Pending			US 91783517	19911028
	Pending			US 92816205	19920102
Priority				US 93144779	19931028
				US 92967633	19921028
				US 91783517	19911028
				US 92816205	19920102

Fulltext Word Count: 9813

Abstract:
This invention provides methods of modulating the immune system by administering peptides of the formula R'-Glx-Glx-Lys-R" (SEQ ID NO:1) in which Glx is Glu or Gln. In particular, this invention provides the use of peptides Thr-Ala-Glu-Glu-Lys (SEQ ID NO:34) and Thr-Pro-Glu-Glu-Lys (SEQ ID NO:33).

7/3,AB/37 (Item 6 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

3830700
Derwent Accession: 1992-234376
Utility
REASSIGNED
C/ Spray-dried antigenic products
Inventor: Newman, Stephen G., Victoria, CA
Kay, William W., Victoria, CA
Assignee: Microtek Research and Development Ltd. (03), Saanichton, CA
Microtek Research and Development Ltd CA (Code: 41491)
Examiner: Sidberry, Hazel F. (Art Unit: 182)
Law Firm: Klarquist Sparkman Campbell Leigh & Whinston, LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5616329	A	19970401	US 94270526	19940705
Continuation	Abandoned			US 90621836	19901204
Priority				US 94270526	19940705
				US 90621836	19901204

Fulltext Word Count: 1633

Abstract:
A method is described for preparing an antigenic product which incorporates exposing an aerosol of a microbial suspension to temperatures at which substantially only the heat stable components of the microbial suspension which retain their immunogenic properties remain. More specifically, the aerosol is exposed to an elevated temperature which denatures all labile components and removes the liquid portion of the aerosol by evaporation.

7/3,AB/38 (Item 7 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

3744627
Derwent Accession: 1996-341511
Utility
C/ Chondroitinase %attenuated% Edwardsiella ictaluri and a %vaccine% for

prevention of enteric septicemia (es) in fish; %GENETIC EN%%GINEERI
Inventor: Shotts, Jr., Emmett B., Athens, GA
Cooper, II, Richard K, Baton Rouge, LA
Assignee: The University of Georgia Research Foundation (02), Athens, GA
Georgia, University of Research Foundation Inc (Code: 14053)
Examiner: Sidberry, Hazel F. (Art Unit: 182)
Law Firm: Needle & Rosenberg

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5536658	A	19960716	US 92965182	19921023
Priority				US 92965182	19921023

Fulltext Word Count: 4748
Abstract:
The present invention provides a chondroitinase %attenuated% Edwardsiella ictaluri bacteria. Further, this invention provides a %vaccine% comprising a protective amount of a chondroitinase %attenuated% strain of Edwardsiella ictduri bacteria and a method for protecting a fish from Enteric Septicemia comprising administering the %vaccine% to the fish.

7/3,AB/39 (Item 8 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

3702472
Derwent Accession: 1994-135564
Utility
C/ %Attenuated% strains of Aeromonas salmonicida useful as fish %vaccines%
Inventor: Thornton, Julian C., Brentwood Bay, CA
Kay, William W., Victoria, CA
Assignee: University of Victoria (03), Victoria, CA
Victoria, University of CA (Code: 21455)
Examiner: Sidberry, Hazel F. (Art Unit: 183)
Assistant Examiner: Krsek-Staples, Julie
Law Firm: Klarquist Sparkman Campbell Leigh & Whinston

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5498414	A	19960312	US 92957531	19921005
Priority				US 92957531	19921005

Fulltext Word Count: 14079
Abstract:
Novel %attenuated% strains of Aeromonas salmonicida are disclosed that are effective as live effective %vaccines% against furunculosis in fish. These %vaccines% may be administered by the immersion of fish in a solution of the %vaccine%. Methods of producing these strains and other strains having the identifying characteristics of these strains are also disclosed.

7/3,AB/40 (Item 9 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

3542404
Derwent Accession: 1994-324520
Utility
C/ %Vaccine% to control the viral infection of fish; %AGAINST% INFECTIOUS HEMATOPOIETIC NECROSIS VIRUS
Inventor: Leong, Jo-Ann C., Albany, OR
Assignee: State of Oregon Acting By and Through The State Board of Higher

Education on Behalf of Oregon State University (02), Euge OR
Oregon State University (Code: 26066)
Examiner: Nucker, Christine M. (Art Unit: 183)
Assistant Examiner: Smith, Lynette F.
Law Firm: Klarquist Sparkman Campbell Leigh & Whinston

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5354555	A	19941011	US 9327742	19930308
Continuation	Abandoned			US 88239775	19880902
CIP	Abandoned			US 85722130	19850410
Priority				US 9327742	19930308
				US 88239775	19880902
				US 85722130	19850410

Fulltext Word Count: 9962

Abstract:
Subunit %vaccines% and their use for immunizing fish against infection by viruses are disclosed. In particular, plasmid pG8 is constructed by joining, with the plasmid pUC8, DNA which encodes the glycoprotein of infectious hematopoietic necrosis virus (IHNV). E. coli cells are transformed by pG8, whereby pure viral antigen is produced to provide a %vaccine% for the control of IHNV in fish.

7/3,AB/41 (Item 10 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

3465125
Derwent Accession: 1989-324079
Utility
EXPIRED
C/ Fish %vaccine% comprising an avirulent, invasive bacterium; %IMMUNOG% ENIC MUTANT STRAIN OF FISH BACTERIUM; PROTECTION AGAINST VIBRIO AND AEROMONAS FISH PATHOGENS
Inventor: Wolf-Watz, Hans, Ume.ang., SE
Norquist, Anders, Ume.ang., SE
Hagstrom, Ake, Hornefors, SE
Assignee: Symbicom Aktiebolag (03), Ume.ang., SE
Symbicom AB SE (Code: 21342)
Examiner: Nucker, Christine M. (Art Unit: 183)
Assistant Examiner: Sidberry, H.
Law Firm: Foley & Lardner

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5284653	A	19940208	US 90601688	19901031
PCT	WO 8909616		19891019	WO 89DK75	19890406
		371:	19901031		
		102e:	19901031		
Priority				DK 189788	19880407

Fulltext Word Count: 7802

Abstract:
A live %vaccine% comprising an avirulent, invasive and immunogenic strain of a fish pathogenic bacterial species is used for immunization of fish against infectious diseases caused by fish pathogens by immersion of the fish into a suspension of the %vaccine% strain. Suitable strains for the preparation of said %vaccine% include %Vibrio% %anguillarum% strains DSM 4506, DSM 4507 and DSM 4508.

7/3,AB/42 (Item 11 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

2309457
Derwent Accession: 1980-71451C
Utility
C/ Spray immunization of fish; OUT OF WATER WITH KILLED VIBRIO OR AEROMONAS OR FURUNCULOSIS BACTERINS
Inventor: Garrison, Robert L., Corvallis, OR
Gould, Rowan W., Corvallis, OR
O'Leary, Patrick J., Corvallis, OR
Fryer, John L., Corvallis, OR
Assignee: The United States of America as represented by the Secretary of the Interior (06), Washington, DC
U S OF AMERICA INTERIOR SECRETARY OF (Code: 86576)
Examiner: Daus, Donald G. (Art Unit: 122)
Assistant Examiner: Eakin, M. C.
Combined Principal Attorneys: Sadowsky, Gersten; Gardiner, Donald A.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 4223014	A	19800916	US 78903430	19780508
Continuation	Abandoned			US 77769128	19770216
Priority				US 78903430	19780508
				US 77769128	19770216

Fulltext Word Count: 1974

Abstract:
A method for immunizing fish against disease by spraying with %vaccine% or bacterin.

7/3,AB/43 (Item 12 from file: 654)
DIALOG(R)File 654:US PAT.FULL.

2080362
Derwent Accession: 1977-16370Y
Utility
DISCLAIMER/DEDICATION **See File 123 for details
C/ Immersion method for treating aquatic animals; HYPEROSMOTIC
Inventor: Ament, Roland W., Arvada, CO
Fender, Daniel C., Seattle, WA
Assignee: Wildlife Vaccines, Inc. (02), Wheat Ridge, CO
WILDLIFE VACCINES INC (Code: 00203)
Examiner: Rosen, Sam (Art Unit: 125)
Law Firm: Beveridge, DeGrandi, Kline

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 4009259	A	19770222	US 75619434	19751003
Priority				US 75619434	19751003

Fulltext Word Count: 8062
Abstract:
Hyperosmotic immersion method for treating water-living animals is disclosed. The animals are immersed in a hyperosmotic solution and thereafter are immersed in a health or welfare enhancing medium.

7/3,AB/44 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0203309 DBR Accession No.: 96-14080
Overcoming a defect in generalized recombination in the marine fish pathogen %Vibrio% %anguillarum% 775: construction of a recA mutant by marker exchange - with the kanamycin-resistance gene for use as a live %attenuated% recombinant %vaccine%
AUTHOR: Singer J T; Ma C; Boettcher K J
CORPORATE AFFILIATE: Univ.Maine
CORPORATE SOURCE: Department of Biochemistry, Microbiology and Molecular Biology, 5735 Hitchner Hall, University of Maine, Orono, ME 04469-5735, USA. email:jsinger@maine.maine.edu
JOURNAL: Appl.Environ.Microbiol. (62, 10, 3727-31) 1996
ISSN: 0099-2240 CODEN: AEMIDF
LANGUAGE: English
ABSTRACT: A modified marker exchange technique that is generally useful in overcoming the recombinational defect in %Vibrio% %anguillarum% 775 and H775-3 and can be used for the creation of a variety of specific chromosomal mutations in this strain was developed. The technique was used successfully for the construction and characterization of a V. anguillarum H775-3 recA mutant. A recombinant cosmid carrying the recA gene of V. anguillarum 775 in the center of a 25 kb cloned DNA insert was first isolated by complementation of methyl methanesulfonate sensitivity in Escherichia coli HB101. The recA gene was inactivated by inserting a kanamycin-resistance gene into recA and the mutant gene was subsequently introduced into V. anguillarum H775-3 by conjugal mobilization. Isolation of recombinants was facilitated by the introduction of an incompatible plasmid and Southern blot hybridization was used to verify the presence of recA::kan in the chromosomal DNA. This recA mutant may be useful in the construction of genetically tailored strains for use as live %attenuated% recombinant %vaccines%. (29 ref)

7/3,AB/45 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0136601 DBR Accession No.: 92-09093
Protecting fish against vibriosis by immunization with genetically %attenuated% live %Vibrio% %anguillarum% - live %vaccine% attenuation for use in fish farming (conference abstract)
AUTHOR: Singer J T; Schmidt K A; Hopper C A
CORPORATE SOURCE: University of Maine, Orono, ME 04473, USA.
JOURNAL: Abstr.Gen.Meet.Am.Soc.Microbiol. (92 Meet., 156) 1992
CODEN: 0005P
LANGUAGE: English
ABSTRACT: %Vibrio% %anguillarum% 775 harboring virulence plasmid pJM1 (65 kb) is responsible for vibriosis in marine fish, a disease which results in high mortalities in farmed salmonids. The plasmid harbors genes encoding an aggressive ferric iron sequestering system consisting of the siderophore anguibactin and a membrane-associated ferric-anguibactin transport system. V. anguillarum 775 (plasmid pJM1-kan2) contains a non-transposable 1.5 kb kanamycin-resistance determinant inserted within a gene required for virulence of V. anguillarum. When tested for virulence in rainbow trout, V. anguillarum 775 (pJM1-kan2) exhibited a 250,000-fold attenuation compared with the wild-type. Live V. anguillarum 775 (pJM1-kan2) was compared with a commercial killed %vaccine% in laboratory-scale %vaccine% trails that included vaccination followed by challenge 3 wk later, and vaccination plus a booster immunization 3 wk later, followed by challenge. In comparative LD50 studies, vaccination with V. anguillarum 775 (pJM1-kan2) conferred protection against wild-type V. anguillarum 775 at a 1,000-fold lower dosage compared with the commercial killed %vaccine%. (0 ref)

7/3,AB/46 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0002908 DBR Accession No.: 82-01908 PATENT
Production of %vaccine% against fish vibriosis - by growing %Vibrio% %anguillarum% in iron-limiting medium to induce production of the outer membrane protein OM2
PATENT ASSIGNEE: Univ.Washington 1982
PATENT NUMBER: WP 8202491 PATENT DATE: 820805 WPI ACCESSION NO.: 82-68230E (6832)
PRIORITY APPLIC. NO.: US 225764 APPLIC. DATE: 810116
NATIONAL APPLIC. NO.: WP 8239 APPLIC. DATE: 820115
LANGUAGE: English
ABSTRACT: Production of a %vaccine% against %Vibrio% %anguillarum% and closely related species is carried out by growing V. anguillarum cells in a fe-limiting medium. This induces the production of the outer membrane protein OM2 (mol. wt. 86,000 dal). The induced cells are then %attenuated% for %vaccine% use or the isolated OM2 itself can be used. The %vaccine% is highly effective in protecting salmon and related fish against vibriosis caused by many of the virulent strains of V. anguillarum. The Fe concentration in the growth medium should be less than 4 uM. The outer membrane protein OM3 (mol. wt. 79,000) may also be produced. The bacteria may be V. anguillarum or non-pathogenic host cells carrying a virulence plasmid which encodes at least a substantial portion of OM2. (16pp)

7/3,AB/47 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent

Dialog Acc No: 3557443 IFI Acc No: 0130360
Document Type: C
METHOD FOR GENERATING NONPATHOGENIC INFECTIOUS PANCREATIC NECROSIS VIRUS (IPNV) FROM SYNTHETIC RNA TRANSCRIPTS; PREPARING CDNA OF INFECTIOUS PANCREATIC NECROSIS VIRUS GENOME, INITIATING REPLICATION OF DS RNA IN HOST CELL USING RNA DERIVED FROM CDNA, INCUBATING HOST CELL IN CULTURE MEDIUM, AND ISOLATING LIVE, INFECTIOUS PANCREATIC NECROSIS VIRUS
Inventors: Vakharia Vikram N (US); Yao Kun (US)
Assignee: Maryland, University of
Assignee Code: 52744
Publication (No,Date), Applic (No,Date):
US 6274147 20010814 US 99282147 19990331
Publication Kind: B
Calculated Expiration: 20190331
Priority Applic(No,Date): US 99282147 19990331
Provisional Applic(No,Date): US 60-80178 19980331

Abstract: A system for the generation of live, nonpathogenic infectious pancreatic necrosis virus (IPNV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDNA clones were constructed which contained the coding and non-coding regions of RNA segments A and B of IPNV, respectively. Segment A was modified to prevent the expression of NS protein. Synthetic RNAs of both segments were produced by in vitro transcription of linearized plasmids with T7 RNA polymerase. Transfection of CHSE cells with combined plussense transcripts of both segments generated infectious virus. The development of a system for producing NS protein deficient IPNV will greatly facilitate studies of viral pathogenesis, and the development of live %attenuated% %vaccines% for IPNV.

7/3,AB/48 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00620337
%ATTENUATED% STRAINS OF AEROMONAS SALMONICIDA USEFUL AS FISH %VACCINES%
ALS FISCHIMPFSTOFF ANWENDBARE ATTENUIERTE AEROMONAS SALMONICIDA-STAMME
SOUCHES AFFAIBLIES D'AEROMONAS SALMONICIDA UTILISEES COMME VACCINS POUR

POISSONS
PATENT ASSIGNEE:
UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION, (1788150), 3800 Finnerty Road, Victoria, British Columbia V8W 2Y2, (AU), (applicant designated states: DE;FR;GB;IE)
INVENTOR:
THORNTON, Julian, C., 971 Josephine Lane, Brentwood Bay, British Columbia V0S 1A0, (CA)
KAY, William, W., 1608 Hampshire Road, Victoria, British Columbia V8R 5T5, (CA)
LEGAL REPRESENTATIVE:
Roth, Ernst Adolf Michael et al (24051), GOTEBORGS PATENTBYRA AB Box 5005, 402 21 Goteborg, (SE)
PATENT (CC, No, Kind, Date): EP 666904 A1 950816 (Basic)
EP 666904 B1 971229
WO 9407995 940414
APPLICATION (CC, No, Date): EP 93921758 931004; WO 93CA403 931004
PRIORITY (CC, No, Date): US 957531 921005
DESIGNATED STATES: DE; FR; GB; IE
INTERNATIONAL PATENT CLASS: C12N-001/20; C12N-015/01; A61K-039/02; C12N-001/20; C12R-001/01
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9712W3	323
CLAIMS B	(German)	9712W3	308
CLAIMS B	(French)	9712W3	389
SPEC B	(English)	9712W3	12120
Total word count - document A			0
Total word count - document B			13140
Total word count - documents A + B			13140

?